None
Quote | Outlook Therapeutics Inc. (NASDAQ:OTLK)
Last: | $8.61 |
---|---|
Change Percent: | -2.06% |
Open: | $8.93 |
Close: | $8.61 |
High: | $9.26 |
Low: | $8.53 |
Volume: | 266,349 |
Last Trade Date Time: | 04/17/2024 03:00:00 am |
News | Outlook Therapeutics Inc. (NASDAQ:OTLK)
ISELIN, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the US and the EU, today announced that it has closed...
2024-03-31 09:25:35 ET Summary The positive CHMP opinion could mean possible European Approval; European Commission expected to decide upon approval for this in the next few months. Phase 3 NORSE EIGHT study underway using ONS-5010 for the treatment of patients with Wet-AMD; Data ...
Message Board Posts | Outlook Therapeutics Inc. (NASDAQ:OTLK)
Subject | By | Source | When |
---|---|---|---|
znewcar1: OTLK 21% v25,6M c1.79 f162M H1.85 morning pop got S@1.55 then sideways strong aft | znewcar1 | investorshangout | 02/04/2021 11:15:59 PM |
znewcar1: OTLK 27% v28,8M c1.47 f127M H1.65 got S@1.35 | znewcar1 | investorshangout | 02/03/2021 10:35:16 PM |
znewcar1: OTLK 20% v6,6M c1.050 f91,3M H1.09 S.92 | znewcar1 | investorshangout | 05/27/2020 8:59:40 PM |
znewcar1: OTLK 48% v6,0M c.875 f38M late day BO over .65 S@.7 then HOD.95 S.81 | znewcar1 | investorshangout | 01/03/2020 12:46:38 AM |
znewcar1: OTLK 53% v6,1M c1.59 f28,M H 1.74 After hour gap and fad then @10 BO1.19 H1.74 S1.50 and e | znewcar1 | investorshangout | 12/03/2019 9:15:47 PM |
News, Short Squeeze, Breakout and More Instantly...
Outlook Therapeutics Inc. Company Name:
OTLK Stock Symbol:
NASDAQ Market:
ISELIN, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to achieve the fi...
ISELIN, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the US and the EU, today announced that it has closed...
Although U.S. stocks closed mixed on Thursday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidenc...